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Induced pluripotent stem cells 
from subjects with Lesch‑Nyhan 
disease
Diane J. Sutcliffe1,12, Ashok R. Dinasarapu2,12, Jasper E. Visser3,4, Joery den Hoed1, 
Fatemeh Seifar1,5, Piyush Joshi1, Irene Ceballos‑Picot6, Tejas Sardar1, Ellen J. Hess1,5,7, 
Yan V. Sun8, Zhexing Wen1,9,10, Michael E. Zwick2,11 & H. A. Jinnah1,2,5,11*
Lesch‑Nyhan disease (LND) is an inherited disorder caused by pathogenic variants in the HPRT1 
gene, which encodes the purine recycling enzyme hypoxanthine–guanine phosphoribosyltransferase 
(HGprt). We generated 6 induced pluripotent stem cell (iPSC) lines from 3 individuals with LND, 
along with 6 control lines from 3 normal individuals. All 12 lines had the characteristics of pluripotent 
stem cells, as assessed by immunostaining for pluripotency markers, expression of pluripotency 
genes, and differentiation into the 3 primary germ cell layers. Gene expression profiling with RNAseq 
demonstrated significant heterogeneity among the lines. Despite this heterogeneity, several 
anticipated abnormalities were readily detectable across all LND lines, including reduced HPRT1 
mRNA. Several unexpected abnormalities were also consistently detectable across the LND lines, 
including decreases in FAR2P1 and increases in RNF39. Shotgun proteomics also demonstrated several 
expected abnormalities in the LND lines, such as absence of HGprt protein. The proteomics study 
also revealed several unexpected abnormalities across the LND lines, including increases in GNAO1 
decreases in NSE4A. There was a good but partial correlation between abnormalities revealed by the 
RNAseq and proteomics methods. Finally, functional studies demonstrated LND lines had no HGprt 
enzyme activity and resistance to the toxic pro‑drug 6‑thioguanine. Intracellular purines in the LND 
lines were normal, but they did not recycle hypoxanthine. These cells provide a novel resource to 
reveal insights into the relevance of heterogeneity among iPSC lines and applications for modeling 
LND.
Lesch-Nyhan disease (LND) is an inherited disorder caused by pathogenic variants in the HPRT1  gene1. The 
variants result in deficiency of a purine recycling enzyme, hypoxanthine–guanine phosphoribosyltransferase 
(HGprt)2,3. This enzyme is ubiquitously expressed in all tissues of the body at all stages of  development4. HGprt 
deficiency produces pleiotropic clinical effects including overproduction of uric acid leading to kidney stones 
and  gout5, brain  abnormalities6–8, and macrocytic  anemia9.
Many experimental models have been developed for LND. Animal models have been produced by knocking 
out the Hprt1 gene in  mice10,11,  rats12 and  rabbits13. Several studies have described spontaneous or induced muta-
tions in immortalized rodent cell  lines14–20. However, rodents do not exhibit the clinical features seen in affected 
 humans21,22. One of the reasons for the lack of overt abnormalities in rodents may be that purine metabolism 
differs across species. For example, purine turnover is at least tenfold higher in rodents compared to primates. 
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Rodents also express certain enzymes that are lacking in humans, such as uricase, which protects rodents from 
excess uric  acid23–25. There are also substantial differences in organ development, particularly for the brain. Thus, 
species differences in purine metabolism or neurodevelopmental mechanisms have led to uncertainty regarding 
the translation of findings from rodent models to humans.
Other experimental models have been derived from human materials, such as blood  cells26–32 or 
 fibroblasts3,33–38 collected from individuals with LND. Some cell models have relied on spontaneous or induced 
mutations in immortalized human cell  lines39–42. One study described human neural stem cells from an aborted 
LND  fetus43, while another focused on partial knockdown of HPRT1 expression in a human induced pluripotent 
stem cell (iPSC) line and a human embryonic stem cell  line44. These studies of human cells have revealed that 
many of the consequences of HGprt deficiency are cell-specific42,45. Three reasons account for these cell type-
specific differences. First, HGprt is expressed ubiquitously; but its level varies across tissues, suggesting that some 
cells are more dependent on HGprt than  others46. Other enzymes of purine metabolism also are expressed at 
different levels in different  tissues47, so downstream and compensatory consequences of HGprt deficiency may 
vary as well. Finally, purines are utilized in different ways by different tissues. For example, rapidly dividing cells 
use purine nucleotides predominantly for RNA synthesis and DNA  replication48. In contrast, post-mitotic cells 
such as neurons do not need large amounts of purine nucleotides for DNA replication, but use nucleotides and 
nucleosides for signaling both within and between  cells49.
Because the consequences of HGprt deficiency vary among different types of cells, the pathogenesis of the 
diferent clinical aspects of HGprt deficiency may need to be studied in different cell types relevant to the differ-
ent clinical features of LND. Induced pluripotent stem cells (iPSCs) derived from patients carrying pathogenic 
variants in the HPRT1 gene provide a novel strategy to study the consequences of HGprt deficiency in different 
lineages. The main goal of the current study was to describe the development and characterization of 6 iPSC lines 
derived from 3 unrelated LND cases as a resource for future studies. The first part of the manuscript describes the 
generation and characterization of the novel iPSC lines. The second part describes gene and protein expression 
abnormalities consistently found among the LND lines. The final part presents a functional characterization of 
the LND lines in relation to purine metabolism.
Results
Selection of fibroblasts for reprogramming. From a collection of fibroblast cultures of 47 cases of 
HGprt deficiency, several criteria were used to select candidates for reprogramming. First, the mutation should 
be stable with a known consequence for HGprt enzyme function. Second, the mutation should be associated 
with multiple unrelated LND patients to ensure a consistent relationship with the clinical phenotype. Third, 
cultures from relatively young patients should be available, because age affects reprogramming efficiency and 
frequency of acquired genetic  variants50. With these criteria in mind, three unrelated cases were selected, all with 
the classic LND phenotype that included overproduction of uric acid, motor and cognitive disability, and self-
injurious behavior. Two involved hot-spot variants leading to different stop codons (c.151C>T and c.508C>T) 
and one was frame-shifting mutation (c.371insTT). All of these variants lead to low mRNA levels due to non-
sense-mediated decay, as well as null enzyme function. Control fibroblast cultures were selected from a bank 
of 20 normal individuals free of any known medical or neurological problems. Because LND is inherited in an 
X-linked recessive manner, all cases and controls were males (Table 1).
Characterization of iPSC lines. At the morphological level, all 6 LND and all 6 control lines grew in 
rounded colonies with defined borders typical of other iPSC lines (Fig. 1). All showed immunostaining char-
acteristics typical of pluripotency including expression of SSEA3, SSEA4, TRA-1-60, TRA-1-80, and Nanog 
(Fig. 1). Complete gene expression profiles were determined by RNAseq, with the percentage of mapped reads 
ranging between 88.8 and 91.7%. A total of 23,748 genes were detected. After filtering genes expressed at very 
low levels, 17,113 genes remained for quantification. All of the lines expressed genes typically associated with 
pluripotency, with no apparent differences between LND and control lines (Fig. 1). All lines were capable of dif-
ferentiating into each of the three main germ cell layers as shown by immunostains (Fig. 2) for ectoderm (PAX6, 
Table 1.  Subject characteristics. a Age relates to subject age at skin biopsy. b Clinical features of classic LND 
include motor dysfunction resembling cerebral palsy, cognitive impairment, self-injurious behavior, and 
overproduction of uric acid.
LND Cases Healthy controls
A D T A B C
Sex Male Male Male Male Male Male
Agea 15 10 46 21 43 22
Race Black Caucasian Caucasian Caucasian Black Caucasian
HPRT1 gene variant c.151C > T c.508C > T c.371insTT none none none
HGprt consequence Premature stop Premature stop Frame shift, premature stop Normal Normal Normal







































































































































































Figure 1.  Pluripotency characteristics. This figure shows a phase-contrast photomicrograph of typical colonies 
for all 6 LND and all 6 control lines, along with immunostains for pluripotency markers (SSEA3, SSEA4, TRA-
1-60, TRA-1-80, Nanog). All cultures were stained simultaneously, and all photomicrographs were taken using 
the same microscope settings. Scale bar is shown at bottom right and depicts 200 μM. Gene expression profiling 
shown as box plots at the bottom of the figure reveal that the control and LND lines expressed similar levels of 
genes associated with pluripotency.
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Figure 2.  Trilineage differentiation. This figure shows the differentiation of all 6 LND and all 6 control lines into 
the 3 primary germ cell layers via merged immunostains for ectoderm (PAX6 = green, nestin = red), mesoderm 
(Brachyury = green, NCAM = red), and endoderm (SOX17 = green, FOXA2 = red). All cultures were stained 
simultaneously, and all photomicrographs were taken using the same microscope settings. Distinct red or green 
colors are evident for ectoderm, where the markers were often expressed in different cells. Shades of orange and 
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NESTIN), mesoderm (Brachyury, NCAM), or endoderm (SOX17, FOXA2). Over several different staining runs, 
with or without a nuclear counterstain, there were no obvious differences between the LND and control lines.
RNAseq data for all iPSC lines were queried to assess for genetic variants in HPRT1. Each of the LND lines 
harbored genetic variants expected from their starting fibroblast lines (Table 1, Supplementary Fig. S1). The 
nonsense variant c.151C>T was confirmed for lines LND29 and LND30. The nonsense variant c.508C>T was 
confirmed for lines LND9 and LND12. The frame-shifting variant c.371insTT was confirmed for LND2 and 
LND4. All of these variants were independently confirmed by sequencing RT-PCR products. No other HPRT1 
sequence variants were detected in the LND iPSC lines and no variants were detected in any of the 6 control iPSC 
lines. Karyotypes were normal for all LND and control lines, except for line LND30 where 11/20 metaphases 
demonstrated an unbalanced translocation affecting the long arm of chromosome 1, with a karyotypic profile 
of 46,XY51/46,XY,t(1:10)(p36.3;q11.1)51 (Supplementary Fig. S2). Although karyotypically abnormal lines may 
yield idiosyncratic results, this line was not discarded, but results were censored so that it could be compared 
against the other karyotypically normal lines.
Differential gene expression in LND and control iPSCs. The RNAseq data were next evaluated to 
identify differences in gene expression between the LND (n = 6) and control (n = 6) lines. With a minimum 
threshold of 1.5 × change and correcting for multiple comparisons with FDR method, differential gene expres-
sion using DESeq2 method revealed significant differences for 3555 genes at FDR < 0.10, 1797 transcripts at 
FDR < 0.05, and 413 transcripts at FDR < 0.01 (Fig. 3A). Differential gene expression using the edgeR method 
revealed significant differences for 1108 transcripts at FDR < 0.10, 407 transcripts at FDR < 0.05, and 69 tran-
scripts at FDR < 0.01 (Fig. 3A). These results demonstrate that these commonly used methods for differential 
gene expression yield different outcomes. However, at FDR < 0.05, almost all transcripts (403 transcripts, 99%) 
were common to both the DESeq2 and edgeR methods (Fig. 3B). As shown in volcano plots (Fig. 3C) and heat 
map (Fig. 3D), the most prominently increased transcript was RNF39 (ring finger protein 39). The most promi-
nently reduced transcripts were HPRT1 and FAR2P1 (fatty acyl-coA reductase pseudogene 1). All three of these 
prominently altered transcripts in RNAseq were confirmed via qPCR using independently collected samples 
from each line (Supplementary Fig. S3). The significant decrement in HPRT1 transcripts provides a useful posi-
tive control, because such a reduction is consistent with the fact that the genetic variants included here are all 
subject to nonsense-mediated mRNA decay.
Genes that were differentially expressed via either the edgeR and DESeq2 methods were next subject to Inge-
nuity Pathway Analysis. Although these methods revealed somewhat different lists of differentially expressed 
transcripts, they produced similar results for affected biological pathways (Fig. 3E). Of the top 10 pathways 
selected based on p-value and z-scores, two were significantly reduced (tRNA charging and NRF2-mediated 
oxidative stress) and 8 were significantly increased (Role of NFAT in cardiac hypertrophy, GPCR-mediated 
nutrient sensing in enteroendocrine cells, androgen signaling, synaptic long-term depression, endocannabinoid 
neuronal synapse pathway, G beta gamma signaling, calcium signaling, and relaxin signaling).
Shotgun proteomics in LND and control iPSCs. An unbiased shotgun approach was used to compare 
the proteomes of the LND (n = 6) and control (n = 6) iPSC lines. After filtering peptides with low expression, a 
total of 33,648 peptides mapping to 2,493 proteins were quantified. The proteomics dataset provided quantitative 
data for 12 proteins associated with pluripotency (ACACA, ACLY, CDH1, DNMT1, DNMT3A, FASN, RBM3, 
SOX2, SLC25A1, VIM, YAP1, ZIC2). None of these were significantly different between LND and control iPSCs 
(not shown).
The proteomics data were next evaluated to identify differences in protein expression between the LND and 
control lines. There were 7 significant protein changes at FDR < 0.10 (Fig. 4B). Five proteins were decreased 
(HGprt, NSE4A/EID3, MPU1, TOIP1, PDIA2, GNAO, PDIA3), and 2 proteins were increased (GNA0, ATPK) 
(Fig. 4C). Two of these protein changes remained significant at FDR < 0.01 (Fig. 4D). One was HGprt, as expected 
for the types of mutations involved. In fact, comparison of the raw vs imputed proteomics data implied a com-
plete absence of HGprt protein in all of the LND samples (Fig. 4E). The other peptide significantly reduced at 
FDR < 0.01 mapped to both NSE4A (non-structural maintenance of chromosomes element 4, homolog A) and 
EID3 (EP300 interacting inhibitor of differentiation 3, a paralog of NSE4A). Both the raw and imputed data for 
NSE4A/EID3 implied a complete absence in all LND iPSCs. Reductions in HGprt and NSE4A were confirmed 
using Western blotting in independently collected samples from all the lines (Supplementary Fig. 4).
Comparison of RNAseq and proteomics results. Among 2493 proteins identified, 2444 mapped to 
genes simultaneously quantified by RNAseq. Overall, there was a good quantitative correlation between the 
results from proteomics and RNAseq (Fig. 4A) for both the control (R = 0.58) and LND lines (R = 0.55). These 
correlations fall in the range of other studies that compared RNAseq and proteomic data generated from the 
same  samples51. The lack of strict correlation between these methods is known to result from post-transcrip-
tional, post-translational, and other mechanisms not detected by either method.
Among the analytes that were most significantly different between control and LND lines, RNAseq and pro-
teomics revealed significantly reduced HPRT1 transcripts and HGprt protein. However some of the transcripts 
significantly different between LND and controls in the RNAseq dataset were not significantly different in the 
proteomics study. For example FAR2P1 is a pseudogene, so no protein was detected by proteomics. RNF39 was 
significantly increased in the RNAseq dataset, but was not detectable in the proteomics dataset. Thus some of 
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Conversely, some statistically significant differences in the proteomics dataset between control and LND 
iPSCs were not significant in the RNAseq dataset. For example, a peptide mapping to both EID3 and NSMCE4 
was detected in control iPSCs, but absent in LND iPSCs. However, the RNAseq revealed no significant change 
in either transcript (NSMCE4, p = 0.45; EID3, p = 0.23). Two other proteins significantly altered in the proteom-
ics study also were not significantly altered by RNAseq. These proteins included ATPK (gene symbol ATP5JK 
or ATP5MF, p = 0.11) and GNAO (gene symbol, GNAO1, p = 0.24). ATPK is involved in synthesis of the purine 
ATP and GNAO is regulated by the purine GTP, so changes at the protein level may reflect post-transcriptional 
alterations caused by changes in intracellular purine metabolism in HGprt-deficient cells. Three other proteins 
significantly altered in the proteomics study were not significantly altered in the RNAseq study when statisti-
cally correcting for multiple comparisons, but they showed clearly significant trends in the same direction as 
proteomics when uncorrected. These proteins included PDIA3 (gene symbol PDIA3, p = 0.010), MPU1 (gene 
symbol MPU1, p = 0.011), TOIP1 (gene symbol, TOR1AIP1, p = 0.025). Thus some of the apparent discrepancies 
between the RNAseq and proteomics datasets reflect the limits of statistical methods in RNAseq and proteom-
ics, and some have argued that corrections for multiple comparisons using the FDR method are inappropriately 
stringent for  proteomics52. These comparisons highlight the many different reasons that RNAseq and proteomics 
datasets from the same samples typically show imperfect correlations ranging from 0.40 < R < 0.6051.
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Figure 3.  Transcriptome analysis. Gene expression profiles were evaluated by RNAseq for all LND (n = 6) and 
control (n = 6) lines. Differential gene expression differed according to both analytical method (edgeR, DESeq2) 
and statistical threshold (A). However, 403 genes were differentially expressed using both methods at FDR < 0.05 
(B). For both edgeR and DESeq2 methods, volcano plots (C) consistently demonstrate 2 genes to be expressed at 
markedly lower levels in the LND lines (HPRT1 and FAR2P1), and 1 gene to be expressed at higher levels in the 
LND lines (RNF39). The red color shows genes with FDR < 0.05 and fold change > 2. The blue color shows genes 
with FDR < 0.05 and fold change < 2. Green and gray show gene changes with FDR > 0.05. Individual variation 
among the lines is shown as a heatmap of gene expression (D). Red depicts higher gene expression and green 
depicts lower expression. Considering only the 403 genes differentially expressed using both edgeR and DESeq2 
at FDR < 0.05, 19 pathways appeared to be significantly different when comparing the LND and control lines (E). 
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Functional assessment of LND iPSCs. To assess the functional effect of the HPRT1 genetic variants, all 
6 LND and all 6 control lines were evaluated using an assay for HGprt enzyme activity. HGprt enzyme activity 
was readily detectable in all control iPSCs (Fig. 5A). Functional HGprt enzyme activity was absent from all LND 
lines, consistent with the transcriptome and proteome results described above. To further assess the impact of 
the HPRT1 genetic variants on cell growth, cells were grown with or without 6TG, an inert synthetic purine base 
that is phosphorylated into a toxic purine nucleotide, only in cells which have functional HGprt. Overall, the 
average growth rates for the LND and control iPSCs were comparable in the standard culture medium (Fig. 5B). 
All of the control lines showed a clear toxic effect when 6TG was added, while all LND were resistant to it 
(Fig. 5B). These results demonstrate absence of functional HGprt enzyme in all of the LND iPSC lines.
Because HGprt plays a known role in purine salvage (Fig. 5C), purines were measured in all 6 LND and all 6 
control iPSCs by HPLC with photodiode array UV detection. In keeping with other types of cells, the majority of 
intracellular purines were adenine nucleotides (ATP, ADP, AMP), with smaller amounts of guanine nucleotides 
(GTP, GDP, GMP), and trace amounts of several other purines. Multivariate ANOVA revealed no significant 
differences for any of the intracellular purines when comparing the LND vs control lines (Fig. 5D).
Purines accumulated in the tissue culture medium over a 24-h period were also quantified because some 
purines are released from cells to the extracellular environment. In keeping with other types of cells, the tissue 
culture medium contained purine bases and nucleosides, but no detectable nucleotides. Multivariate ANOVA 
revealed significant differences between the LND and control lines for hypoxanthine (Fig. 5D). The LND iPSCs 
released an average of 20 fold more hypoxanthine into the medium than control iPSCs. This result is consistent 
with the known role of HGprt in recycling hypoxanthine into purine nucleotides. Uric acid levels were undetect-
able in both LND and control iPSCs, implying that the oxidase form of xanthine oxidoreductase (XOR) is not 
active in these cells (Fig. 5D).
Although HGprt deficiency is the primary biochemical defect in LND, it is known to produce numerous 
downstream secondary changes in purine metabolism, such as increases in purine synthesis. We therefore inter-
rogated the RNAseq data for changes the expression of other genes encoding proteins known to be involved in 
purine metabolism. Among the 109 purine-related genes in the KEGG pathway for purine metabolism, only 6 
were significantly different in the LND vs control iPSC lines at FDR < 0.05 (Fig. 5E). This result implies that any 
secondary changes in purine metabolism that occur in LND, such as increases in purine synthesis, may result 
from post-transcriptional mechanisms. This suggestion is consistent with prior studies have shown that many 
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Figure 4.  Proteomics analysis. Protein expression profiles were evaluated by shotgun proteomics for all 
LND (n = 6) and control (n = 6) lines. There was a good quantitative correlation between the gene and protein 
expression results for both the LND and control lines (A). Only 7 proteins reached statistical thresholds for 
differential expression at FDR < 0.10 (B). Individual variation for among the lines for the 7 proteins meeting the 
FDR < 0.10 criterion is shown as a heatmap (C). Red depicts a higher gene expression and green depicts lower 
gene expression. Only 2 proteins remained significantly different between LND and control at FDR < 0.01, and 
a volcano plot revealed marked reductions in the levels of both HGprt and NSE4A (D). Red depicts genes with 
p < 0.001 and fold change > 2. Green and gray depict FDR > 0.05. The marked reductions in all LND lines (blue) 
compared to all control lines (red) were confirmed by evaluation of the raw and imputed values for HGprt (E).
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:8523  | https://doi.org/10.1038/s41598-021-87955-9
www.nature.com/scientificreports/
availability, release from endogenous feedback inhibitors, post-translational mechanisms, or compartmentaliza-
tion into  purinosomes48,53.
Discussion
The current studies describe the development and characterization of 6 iPSC lines from subjects with classic 
LND, along with 6 iPSC lines from normal healthy individuals for comparisons. All 12 lines have the typical 
characteristics of pluripotent stem cells, as assessed using multiple methods including immunostaining for pluri-
potency markers, expression of mRNA transcripts for pluripotency genes, and directed differentiation into the 
3 primary germ cell layers (endoderm, ectoderm, and mesoderm). These cells provide novel tools for studying 
the pathogenesis of LND, as well as novel insights into the biology of iPSCs and their use for disease modeling.
Relevance for iPSC biology. Many prior studies have shown an important interplay between pluripo-
tency and metabolism, and especially purine nucleotides such as  ATP54. In addition to driving many energy-
dependent reactions, ATP is required as a building block for DNA and RNA in dividing cells. Mammalian cells 
derive their purine nucleotides from two major sources, de novo purine synthesis and purine  salvage48. However, 
all types of cells do not rely equally on de novo and salvage pathways to maintain purine levels. For example, 
actively dividing stem or neoplastic cells typically rely heavily on de novo synthesis, while terminally differenti-
ated cells tend to depend more on  salvage48,55–57.
Although HPRT1 is listed among the many genes involved in cell  cycling58, our studies imply that iPSCs do 
not require HGprt, because iPSCs with null variants had pluripotency characteristics that were similar to those 
of iPSCs derived from normal individuals (Figs. 1, 2), they grew at rates similar to iPSCs from normal individuals 
(Fig. 5B), and they demonstrated no significant changes in intracellular purines (Fig. 5D). However, all 6 LND 
iPSCs consistently wasted large amounts of purines, as judged by the 20-fold increases in hypoxanthine released 
from cells into the tissue culture medium (Fig. 5D). Because intracellular purine nucleotides were normal in the 
LND iPSCs, this result implies that the de novo pathway for synthesis of new purines is sufficient to compensate 
for any purines potentially lost because of the absence of HGprt-mediated purine salvage in iPSC cells.
Relevance for iPSC disease modeling. Many prior studies of iPSCs derived from subjects with vari-
ous diseases have relied on relatively small numbers of iPSC lines, especially for rare  diseases59. For LND, prior 
Figure 5.  Functional assessment of HGprt deficiency. All control iPSC lines (red, n = 6) demonstrated readily 
detectable activity in the HGprt enzyme assay, while all LND iPSC lines (blue, n = 6) had no detectable activity 
(A). Results are shown as box plots with results for each line shown separately. There was no obvious difference 
in the growth of the control and LND lines in the absence of 6TG (blue lines, B). However, the control lines 
showed a clear toxic effect of 6TG, while the LND lines appeared to be resistant to it (red lines, B). In these 
growth curves, the error bars show the standard deviation. HGprt plays an important role in the metabolism 
of hypoxanthine (C), leading to marked hypoxanthine accumulation that is released into the tissue culture 
medium; with no apparent impact on intracellular purines (D). In this panel, controls are shown in red and 
LND in blue, with error bars reflecting standard deviations. Among 109 genes in the KEGG pathway for purine 
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studies have described only 1–2 iPSC lines, often from a single  individual60,61. Others have described HPRT1 
gene-edited  iPSCs62. However, few characteristics regarding these iPSCs were provided. Many other studies have 
emphasized phenotypic variation among iPSC lines, even those derived from the same  subject63–70. There are 
many causes for this variability including sample source (disease characteristics, type of mutations, background 
genome, sex, age, race, etc.…), cell handling methods (reprogramming method, growth conditions, passage 
level, etc.….), and experimental measures examined (gene expression, protein expression, enzyme activity, 
purines measures, etc.…). Our studies with 6 LND iPSC lines (2 independent lines from each of 3 unrelated 
subjects) provide some insights into the biological relevance of this variability.
On the one hand, our studies confirm significant variation between iPSC lines. For example, the L3.30 line 
acquired a genomic defect involving an unbalanced translocation of chromosome 1. Such chromosomal defects 
are commonly acquired during iPSC production and  growth71,72. Significant variability was also evident across 
iPSC lines in the gene expression studies, with no obvious influence of within-subject or between-subject rela-
tionships (Fig. 3D). In the proteomic studies, line L2.09 demonstrated idiosyncratic results compared to other 
LND lines (Fig. 4C). This variability evident across the 6 LND iPSC lines confirms prior calls for caution when 
relying on a small number of iPSC lines for disease modeling, and calls into question results from prior smaller 
studies of  LND60,61.
On the other hand, despite this variation, some very consistent abnormalities could be detected across the 
LND iPSC lines. For example, it is often claimed that karyotypical defects such as those found in LND30 should 
not be used, because they provide idiosyncratic  results71,72. However, our results show that this line behaved 
similarly to the other 5 LND iPSC lines in all respects studied. Thus this karyotypical defect did not seem relevant 
to the molecular and biochemical consequences of HGprt deficiency. Despite the variation in gene expression, 
consistent abnormalities were clearly detectable for many transcripts. Most notably, consistent abnormalities 
could be detected in the LND iPSC lines for expression of HPRT1 mRNA and protein, enzyme activity, growth 
characteristics with and without 6TG, and certain unexpected findings such as reductions in FAR2P1 mRNA 
(Fig. 3) and NSE4A/EID3 protein (Fig. 4). Thus, biological variation certainly exists among iPSCs, but the 
significance of this variation depends on what is being studied. Our results demonstrate that the most robust 
disease-related abnormalities can be detected despite the variability inherent across iPSC lines.
Relevance for LND. The results described here also demonstrate the value of both hypothesis-driven and 
unbiased approaches to understanding the biology of disease. LND is caused by defects in a known gene encod-
ing a known protein with a known function. This knowledge makes it possible to hypothesize and then verify 
findings from studies using iPSCs, such as reductions in HPRT1 mRNA in gene expression studies, loss of HGprt 
protein in proteomic studies, absence of HGprt enzymic activity, resistance to 6-TG, and specific changes in 
purine metabolism.
The unbiased studies further revealed some novel and unexpected findings relating to the loss of HGprt, such 
as marked and consistent reductions in FAR2P1 mRNA in the LND iPSCs (Fig. 3). The reasons for changes in 
FAR2P1 are not immediately obvious. It is thought to be a pseudogene with no known function. Further, there 
is no obvious connection between FAR2P1 and HPRT1, the known biology of HGprt, or purine metabolism. 
Similarly, there was a significant reduction in a peptide mapping to both NSEA4 and/or EID3 in proteomic 
studies of the LND iPSCs (Fig. 4). Once again, the reasons for these changes are not clear. NSEA4 is thought to 
play a role in maintaining chromosome structure, and EID3 plays a role in suppressing gene transcription from 
nuclear receptors. Neither protein bears any obvious relationship to the biology of HGprt. These findings and 
their relationship to the biology of LND will require further studies.
HGprt deficiency appears to have minimal impact on intracellular purines in iPSCs, possibly because they 
depend more on de novo purine synthesis, rather than purine recycling, for maintaining purines. There are 
significant variations in dependence of different cells on synthesis versus salvage pathways to maintain purines. 
Tissue differences are most obvious in bone marrow cells and particularly mature erythrocytes, which lack a 
functional de novo synthetic pathway because of the absence of the first enzyme in the  pathway45,46,73. Indeed, 
the dependence of erythrocytes on HGprt-mediated salvage of hypoxanthine supplied into the circulation by the 
 liver74 may explain why macrocytic anemia is so common in  LND9,45. Similarly, de novo purine synthesis seems 
to contribute to cell division and neurogenesis in the developing  brain56,75–77, but the mature brain depends more 
on purine  salvage55,56,78. Within the brain, neurons seem to express much more HGprt than  glia79. In keeping with 
the concept that the ratio of de novo synthesis to salvage synthesis of purines is low in the adult brain, the Human 
Protein Atlas indicates high levels of HGprt across almost all brain regions, with variable or low levels of the 6 
enzymes in the de novo pathway (www. prote inatl as. org). However, the distribution and levels of each enzyme 
of purine synthesis in various types of neurons, and whether they can aggregate into purinosomes needed to 
drive purine synthesis, has never been methodically mapped  out47,80,81. Although the exact mechanisms remain 
to be disclosed, the dependence of specific neurons on HGprt-mediated purine salvage to maintain purines may 
explain the prominent neurobehavioral abnormalities of  LND82,83. Thus, certain cell types may experience signifi-
cant purine deficiency in LND, even when the undifferentiated LND iPSCs do not. Hypotheses relating to cell-
specific changes in purines can now be tested by differentiating the LND iPSCs into disease-relevant cell types.
Methods
Fibroblast cultures. All procedures involving human subjects followed appropriate institutional and 
national guidelines and were approved by the Emory University Institutional Review Board. For all control 
subjects who provided data or materials for these studies, informed written consent was obtained. For LND 
subjects who have substantial cognitive impairment and usually cannot hold a pen, informed written consent 
was obtained their legal guardians; verbal assent also was obtained from subjects who could speak. The diagnosis 
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of LND was made according to published criteria and was based on the presence of all elements of the classical 
clinical phenotype including self-injurious behavior, motor impairments, intellectual disability, and evidence for 
overproduction of uric  acid6. The diagnosis was verified by biochemical testing showing reduced HGprt enzyme 
activity in fibroblasts or blood cells and/or an associated genetic variant predicting null HGprt enzyme activity. 
Cultures of human skin fibroblasts were prepared as previously  described3.
Reprogramming methods to generate induced pluripotent stem cells. Fibroblasts were repro-
grammed to iPSCs, using a microRNA/mRNA Reprogramming method (Stemgent, Cambridge MA). Two inde-
pendent lines for each of 3 unrelated LND cases were prepared, for a total of 6 lines. Two independent lines for 
each of 3 unrelated normal controls (n = 6) were prepared in parallel. For each fibroblast culture, one well of a 
6-well plate was seeded with 5.0 ×  103 cells. Twelve days of transfections with in vitro transcribed mRNAs encod-
ing the human transcription factors Oct4, Sox2, Klf4, c-Myc, Lin28 and nGFP mRNA followed. In addition, 
transfections at day 1 and day 5 included a proprietary miRNA cocktail. Colonies began to emerge at day 13–15. 
Colonies with typical iPSC morphology were manually passaged approximately 4 times, before being enzymati-
cally passaged using Accutase (Stemcell Technologies). Cultures were typically maintained on Matrigel-coated 
6-well plates (BD Biosciences) in an atmosphere of 5%  CO2 at 37˚C in mTeSR1 medium (Stemcell Technologies) 
supplemented with 0.5% penicillin–streptomycin. The majority of studies were conducted after 10 passages.
Genetic evaluation of iPSCs. For each iPSC line, one Matrigel-coated T25 flask of cells was grown to 80% 
confluency, harvested, and trypsin G-banded. A minimum of 20 metaphase cells were evaluated for karyotypic 
abnormalities (Wicell Research Institute Cytogenetics Lab, Madison WI). At least 4 metaphases were photo-
graphed with a minimum of 400 band resolution.
The original HPRT1 genetic variant was confirmed in the reprogrammed iPSCs by RT-PCR. RNA was 
extracted using TriZol Reagent (Life Technologies, Carlsbad CA) and the concentration of RNA was determined 
using a NanoDrop spectrophotometer 1000 (Thermo Fisher Scientific, Rockford IL). RT-PCR was performed 
using Superscript One-Step for Long Template Kit (Life Technologies, Carlsbad CA) with 1 µg RNA (forward 
primer GCG AAC CTC TGG GCT TTC , reverse primer AAG CTC TAC TAA GCA GAT GGC CAC AGA ACT AGA). 
After assessing the quality of the product by gel electrophoresis, cDNA was purified using the QIAquick PCR 
purification Kit (Qiagen, Venlo, The Netherlands) and samples, premixed with the primers, were sequenced 
(Genewiz, South Plainfield NJ). The sequencing result was analyzed by aligning it to the sequence of HPRT1 
(NM_000194.2) using BLAST aligning tool.
Assessment of pluripotency. Several methods were used to assess pluripotency potential including 
immunostaining for pluripotency markers (SSEA3, SSEA4, TRA1-60, TRA1-81, NANOG), assessing expres-
sion of pluripotency genes by gene expression profiling, and differentiating the lines towards each of the 3 major 
germ cell layers. Primary antibodies for staining included anti-Tra1-81 (mouse, R&D #MAB8495), Anti-Tra1-60 
(mouse, R&D #MAB4770), Anti-NANOG (rabbit, R&D # AF1997), Anti-SSEA-3 (mouse, R&D #MAB1434) 
or Anti-SSEA-4 (rat, Abcam #ab16287). Secondary antibodies included anti-mouse Alexa Fluor 488 and Alexa 
Fluor 594, anti-rabbit Alexa Fluor 594, anti-rat Alexa Fluor 488 or anti-goat Alexa Fluor 488 (Life Technologies, 
Carlsbad CA) diluted 1:1000 in 5% BSA-PBS. Cells were visualized using an Olympus DP72 Microscope (Olym-
pus, Shinjuku, Tokyo, Japan). All antibodies used had their staining characteristics verified using the previously 
validated KOLF-2 iPSC  line84. All control and LND lines were subject to at least 2 separate staining runs for all 
markers, with or without a nuclear counterstain (DAPI) to identify unstained cells.
The STEMdiff Trilineage Differentiation Kit (Stemcell Technologies, Vancouver BC) was used to assess com-
petence for differentiation into the 3 major germ cell layers (endoderm, ectoderm and mesoderm). For ectoderm, 
antibodies targeted PAX6 (rabbit, Abcam #ab195045) and Nestin (mouse, Stemcell Technologies #60,091). For 
mesoderm, antibodies targeted Brachyury (goat, R&D #AF2085) and NCAM (mouse, Stemcell Technologies 
#60,021). For endoderm, antibodies targeted SOX17 (goat, R&D Systems #AF1924) and FOXA2 (mouse, BD 
Pharmingen #561,580). All lines were subject to at least 2 separate staining runs for all markers, with or without 
a nuclear counterstain (DAPI).
Gene expression profiling. Prior studies of the RNAseq method have suggested ideal comparisons should 
involve at least 6 biological  replicates85. As a result, each of the 6 control and 6 LND lines were grown to approxi-
mately 80% confluency, harvested by enzymatic release and centrifugation. At least 1 million cells per tube were 
flash-frozen in a mixture of ethanol and dry ice, and stored at –80˚C. Once samples from all lines were ready for 
simultaneous processing, RNA was isolated with the Qiagen miRNEasy kit with on-column DNAse treatment. 
Variance from biological replicates is far greater than variance from technical replicates, so the value of technical 
replicates is  limited86. As a result, RNAseq measures were conducted only once for each cell line. RNA concen-
trations were measured with UV absorbance on a Tecan Infinite m200 pro. RNA profiles were assessed with the 
Agilent 2100 Bioanalyzer and Agilent RNA 6000 Nano Chip assay. RNA sequencing (RNA-seq) was conducted 
at HudsonAlpha (Birmingham, Alabama). A total of 50 million paired-end, 100 bp reads were generated per 
library (100 million total reads per sample). Base calling and FASTQ generation were processed using Illumina’s 
HiSeq Control Software version 1.5.15.1 (RTA v1.13.18 and bclfastq v 1.8.3).
Raw Illumina sequencing reads were first checked by FastQC (0.11.4) for quality and then aligned to the 
human indexed reference genome (UCSC RefGene; hg38 build, 26,485 genes) using STAR (Spliced Transcripts 
Alignment to a Reference)87. Quantification of gene expression was done using HTSeq-count88. To improve 
the fidelity of quantitative results, transcripts with very low counts across all libraries were filtered  out89. This 
filtering strategy applied using filterByExpr function (default settings) from the edgeR (3.28.0) package retained 
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17,113 genes for differential expression analyses. Differential expression was examined using both edgeR and 
DESeq2 (1.26.0)86. Raw count data from HTSeq-count were imported into R (version 3.6.1; R Core Team, 2019, 
“R: A language and environment for statistical computing”, R Foundation for Statistical Computing, Vienna, 
Austria. https:// www.R- proje ct. org/) where they were filtered, normalized and identified. For edgeR, counts 
per million (CPM) data were generated with the trimmed method of M-values (TMM), as implemented in the 
Bioconductor package  edgeR90. CPM is defined as read counts scaled by the number of sequenced fragments 
multiplied by 1 million. Correction for multiple comparisons employed the Benjamini–Hochberg method for 
the False Discovery Rate (FDR), and data are expressed at multiple thresholds. DESeq2 involves normalization 
of raw read counts using median ratio normalization where the geometric mean is calculated for each transcript 
across all samples, and the count of a transcript in each sample is then divided by this mean. DESeq2 uses the 
Wald test for significance testing.
Ingenuity Pathway Analysis (Qiagen Bioinformatics, Redwood City CA) was used to group significantly 
affected genes into biological pathways. This analysis was conducted on the 403 transcripts differentially expressed 
between LND and control samples at FDR < 0.05 for both edgeR and DESeq2 methods. Output included two 
statistical measures. The first (p-value) represents the probability that the correlation between the genes entered 
did not occur by chance. The second (activation z-score) represents the degree to which observed changes cor-
relate with the expected changes associated with pathway activation or inhibition. Significant pathway activation 
is reflected by a positive z-score of > 2, (at p < 0.05), while pathway inhibition is indicated by a negative z-score.
Proteomic analyses. At least 1 million cells from each line were harvested as described above for gene 
expression profiles and stored at − 80 °C. Once samples from all lines were ready for simultaneous processing, 
they were subjected to trypsin digestion followed by LC–MS/MS of resulting peptides on an Orbitrap Fusion 
mass spectrometer.
All raw data files were processed together in a single run by MaxQuant (version 1.6.7) with the following 
settings: Group-specific parameters [Variable modifications: Oxidation(M), Acetyl (Protein N-term) and Deami-
dation (NQ); Digestion: trypsin]; Global parameters [Min. peptide length: 6 and Max. peptide mass [Da]: 6000, 
Modifications used for protein quantification: Oxidation(M), Acetyl (Protein N-term) and Deamidation (NQ)]; 
FTMS MS/MS match tolerance: 0.05 Da; Match between runs: true and a maximum of two missed cleavage sites 
were allowed. Database searches were conducted with the Andromeda search engine with the UniProt-SwissProt 
human canonical database as a reference and the database of common laboratory contaminants. MaxQuant 
reports summed intensity for each protein as well as its iBAQ value. Proteins that shared all identified peptides 
were combined into a single protein group. Peptides that matched multiple proteins were assigned to the protein 
group with the most unique peptides. MaxQuant employs the MaxLFQ algorithm for label-free quantification. 
Quantification was performed using unique and multiple-mapping peptides, including those modified by acetyla-
tion (N-terminal), oxidation (methionine), and deamidation (NQ). PTQX was used for general quality  control91.
LFQ intensities of proteins generated from MaxQuant were imported into Perseus (version 1.6.7) to identify 
differentially expressed proteins (DEPs). Briefly, proteins identified as: only identified by site, reverse and contam-
inants were removed and protein group LFQ intensities were log2-transformed to reduce the effect of outliers and 
filtered to have 6 valid values (50% of samples). Missing LFQ values were imputed before performing Student’s 
t-tests. The imputation was achieved by using the “Replace missing values from normal distribution” function. 
Because prior studies have suggested that routine correction for multiple comparisons using the FDR method 
may be too conservative for discovery proteomics, differences are presented with both uncorrected p-values and 
FDR-corrected values. Graphic representations of the data were prepared using either R or GraphPad Prism 8.
Functional assessment of LND lines. The functional consequences of the HPRT1 gene variants were 
assessed using three approaches. The first was a direct enzyme assay for HGprt from tissue extracts, modified 
for cultured cells, and adapted for use in a microplate  platform92. It is based on conversion of radiolabeled 
hypoxanthine into inosine monophosphate (IMP). Individual iPSC cultures were grown in 6 well dishes. Cells 
were detached with Accutase (Stemcell Technologies) into single cell suspensions, pelleted by centrifugation at 
300×g for 4 min, and mixed with 50 µL of assay buffer consisting of 50 mM HEPES and 15 mM  MgCl2. Samples 
were then frozen at − 80 °C for storage. For assay, samples were thawed, sonicated briefly, and centrifuged at 
10,000×g for 10 min. A 10 µL aliquot of each was then incubated in a reaction mixture that contained 100 µM 
[8-14C]-hypoxanthine (50 mCi/mmol, Moravek Biochemicals Inc, CA), assay buffer and 10 mM PRPP (Sigma). 
The assay was allowed to proceed for 30 min at 37 °C. The reaction was then terminated by the addition of 5 μL 
of 2 M PCA. Tubes were then incubated on ice for 15 min to precipitate potassium-perchlorate. Precipitate was 
centrifuged and a 5 µL sample of the supernatant was spotted onto microplates with diethylaminoethyl anion 
exchange filters (Millipore, Billerica MA). Samples were allowed to adsorb for 60 min and free radiolabeled 
substrate was washed from IMP bound to the filters with 200 µL of  H2O followed by 200 µL of 50% methanol (3 
times) by vacuum filtration using a MultiScreen HTS Vacuum Manifold (Millipore). Then 100 µL of ULTIMA 
GOLD MV scintillation liquid (Perkin Elmer, Waltham, MA) was added and plates were stored at room temper-
ature for 24 h before counting with a 2450 MicroBeta Microplate Scintillation Counter (Perkin Elmer, Finland). 
To accommodate slight changes in cell density at harvest, HGprt enzyme activity was normalized to total protein 
concentrations using the Pierce BCA kit (Thermo Fisher Scientific, Rockford IL).
The second approach to functional assessment of the HPRT1 gene variants involved growth in medium sup-
plemented with 6-thioguanine (6TG), an inert prodrug that is phosphoribosylated into a toxic nucleotide by 
 HGprt93. Normal cells expressing HGprt die after 1–2 days of exposure, while HGprt-deficient cells grow nor-
mally. For each iPSC line, 50,000 cells were plated in 24-well plates in mTeSR1 media (Stemcell Technologies), 
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with or without 30 µM 6TG (Sigma A-4660). Medium was replaced every other day. Cells survival was assessed 
on days 2, 4, and 6.
The third approach for functional assessment involved measuring intracellular purine levels and purine waste 
products released into the tissue culture medium. Cultures were grown to 80% confluency in triplicate samples (at 
least 1 million cells per sample). To measure purines released into culture medium, fresh medium was replaced 
24 h before collecting a 450 µL aliquot of the culture medium, and mixed with 50 µL of 1 M perchloric acid and 
stored at − 80 °C. To measure intracellular purines, the cells were removed with Accutase and pelleted at 500×g 
for 5 min. Purines were measured by high performance liquid chromatography with photodiode array ultraviolet 
detection (HPLC–UV) as previously  described3,19,42. This method resolves and quantifies the most abundant 
biologically relevant purines including ATP, ADP, AMP, adenosine, adenine, GTP, GDP, GMP, guanosine, gua-
nine, hypoxanthine, inosine, xanthine and uric  acid17,42. Purine analytes were normalized to total protein with 
the Pierce BCA kit (Thermo Fisher Scientific, Rockford, IL).
Data availability
Data or materials described in this report may be requested from the authors.
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